Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Methods for treating neural cell swelling
US9107932B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9107932-B2 |
| Application number | US-201414184947-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2014 |
| Priority date | Mar 20, 2002 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A composition comprising a novel Ca 2+ -activated, [ATP] i -sensitive nonspecific cation (NC Ca-ATP ) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca] i . The NC Ca-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NC Ca-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NC Ca-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a subject having brain injury or cerebral ischemia, comprising the step of administering an antagonist of a NC ca-ATP channel that blocks the channel, prevents the channel opening, and/or reduces the magnitude of membrane current through the channel, wherein the antagonist is a sulfonylurea compound or a benzamido derivative. 2. The method of claim 1 , wherein the cerebral ischemia is stroke. 3. A…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9107932B2 cover?
- A composition comprising a novel Ca 2+ -activated, [ATP] i -sensitive nonspecific cation (NC Ca-ATP ) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca] i . The NC Ca-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolariz…
- Who is the assignee on this patent?
- Univ Maryland, Us Dept Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7076. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).